Effects of Prior Authorization on Medication Discontinuation Among Medicaid Beneficiaries With Bipolar Disorder

被引:0
|
作者
Zhang, Yuting
Adams, Alyce S. [1 ,2 ]
Ross-Degnan, Dennis [1 ,2 ]
Zhang, Fang [1 ,2 ]
Soumerai, Stephen B. [1 ]
机构
[1] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA
[2] Harvard Pilgrim Hlth Care, Boston, MA USA
基金
美国医疗保健研究与质量局;
关键词
ANGIOTENSIN-RECEPTOR BLOCKERS; STEP-THERAPY; PROGRAM; PHARMACOTHERAPY; SCHIZOPHRENIA; COMORBIDITY; 12-MONTH; DRUGS;
D O I
10.1176/ps.2009.60.4.520
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: Few data exist on the cost and quality effects of increased use of prior-authorization policies to control psychoactive drug spending among persons with serious mental illness. This study examined the impact of a prior-authorization policy in Maine on second-generation antipsychotic and anticonvulsant utilization, discontinuations in therapy, and pharmacy costs among Medicaid beneficiaries with bipolar disorder. Methods: Using Medicaid and Medicare utilization data for 2001-2004, the authors identified 5,336 patients with bipolar disorder in Maine (study state) and 1,376 in New Hampshire (comparison state). With an interrupted time-series and comparison group design, longitudinal changes were measured in second-generation antipsychotic and anticonvulsant use; survival analysis was used to examine treatment discontinuations and rates of switching medications. Results: The prior-authorization policy resulted in an 8-percentage point reduction in the prevalence of use of nonpreferred second-generation antipsychotic and anticonvulsant medications (those requiring prior authorization) but did not increase use of preferred agents (no prior authorization) or rates of switching. The prior-authorization policy reduced total pharmacy reimbursements for bipolar disorder by $27 per patient during the eight-month policy period. However, the hazard rate of treatment discontinuation (all bipolar drugs) while the policy was in effect was 2.28 (95% confidence interval= 1.36-4.33) higher than during the prepolicy period, with adjustment for trends in the comparison state. Conclusions: The small reduction in pharmacy spending for bipolar treatment after the policy was implemented may have resulted from higher rates of medication discontinuation rather than switching. The findings indicate that the prior-authorization policy in Maine may have increased patient risk without appreciable cost savings to the state. (Psychiatric Services 60: 520-527, 2009)
引用
收藏
页码:520 / 527
页数:8
相关论文
共 50 条
  • [41] Impact of Kentucky Medicaid Prior Authorization Removal on Dispensing and Continuity of Buprenorphine for the Treatment of Opioid Use Disorder
    Miracle, Dustin K.
    Hammerslag, Lindsey R.
    Slavova, Svetla
    Lofwall, Michelle
    Talbert, Jeffery
    Walsh, Sharon L.
    Freeman, Patricia R.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 56 - 56
  • [42] Medication compliance among patients with bipolar disorder and substance use disorder
    Weiss, RD
    Greenfield, SF
    Najavits, LM
    Soto, JA
    Wyner, D
    Tohen, M
    Griffin, ML
    JOURNAL OF CLINICAL PSYCHIATRY, 1998, 59 (04) : 172 - 174
  • [43] Changes in Antipsychotic Medication Adherence Among Medicaid Beneficiaries with Schizophrenia During COVID-19
    Shen, Siyuan
    Yang, Catherine
    Candon, Molly
    Lorenc, Emily
    Jang, Min
    Mandell, David
    ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES RESEARCH, 2025, 52 (02) : 277 - 284
  • [44] IMPACT OF PRIOR AUTHORIZATION POLICIES ON ANTIPSYCHOTIC MEDICATION PRESCRIPTION TRENDS IN PRESCHOOL-AGE CHILDREN ENROLLED IN ARKANSAS MEDICAID
    Simpson, Stacy
    Domon, Steven
    Miller, Laurence H.
    Ford-Bowen, Pamela
    Golden, William
    Thapa, Purushottam
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2016, 55 (10): : S158 - S158
  • [45] ANTIPSYCHOTIC MEDICATION PRESCRIPTION TRENDS IN FOSTER CARE CHILDREN ENROLLED IN ARKANSAS MEDICAID FOLLOWING IMPLEMENTATION OF PRIOR AUTHORIZATION POLICIES
    Simpson, Stacy
    Domon, Steven
    Miller, Laurence H.
    Ford-Bowen, Pamela
    Golden, William
    Thapa, Purushottam
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2016, 55 (10): : S201 - S202
  • [46] COST-SHARING AND PRIOR AUTHORIZATION EFFECTS ON MEDICAID SERVICES IN CALIFORNIA .2. REPLY
    KUEHL, AE
    MEDICAL CARE, 1976, 14 (06) : 545 - 546
  • [47] Early effects of an FDA advisory regarding antipsychotics medications on US medicaid prior authorization programs
    Polinski, Jennifer
    Fischer, Michael
    Servi, Amber
    Robinson, Elizabeth
    Wang, Philip
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 : S35 - S35
  • [48] Role of Adverse Effects in Medication Nonadherence in Bipolar Disorder
    Mago, Rajnish
    Borra, Dileep
    Mahajan, Rajeev
    HARVARD REVIEW OF PSYCHIATRY, 2014, 22 (06) : 363 - 366
  • [49] ASSESSING THE IMPACT OF A MEDICAID PRIOR AUTHORIZATION (PA) POLICY FOR DULOXETINE ON ANTIPSYCHOTIC USE AMONG PATIENTS WITH DEPRESSION
    Birnbaum, H. G.
    Ivanova, J. I.
    Waldman, T.
    Swallow, E.
    Cummings, A. K.
    Clark, T.
    Peng, X.
    Swindle, R.
    VALUE IN HEALTH, 2013, 16 (03) : A68 - A69
  • [50] Illness Insight and Medication Adherence Among Patients With Bipolar Disorder
    Gutierrez-Rojas, Luis
    Maria Martinez-Ortega, Jose
    Perez-Costillas, Lucia
    Jimenez-Fernandez, Sara
    Dolores Carretero, Maria
    Gurpegui, Manuel
    JOURNAL OF NERVOUS AND MENTAL DISEASE, 2020, 208 (06) : 481 - 487